Table 1 Demographic and clinical characteristics of the study subjects.

From: Genome-wide association study of the response of patients with diabetic macular edema to intravitreal Anti-VEGF injection

Characteristics

Good responder group

Poor responder group

P-value*

Total, n (female %)

25 (52)

26 (50)

.842

Age, yrs

57.4 ± 11.3

60.2 ± 9.3

.418

DM, duration, yrs

13.6 ± 11.3

13.2 ± 7.3

.082

HbA1c, %

7.23 ± 1.16

7.70 ± 1.35

.201

Hypertension, %

24.0

30.8

.291

Nephropathy, %

36.0

30.8

.445

Dyslipidemia, %

52.0

53.9

.807

Baseline

CST, μm

468 ± 126

675 ± 117

.665

BCVA, logMAR

0.47 ± 0.33

0.49 ± 0.32

.769

After treatment at 6 month

CST, μm

257 ± 32

431 ± 98

 < .001

BCVA, logMAR

0.28 ± 0.23

0.54 ± 0.35

.003

Blood pressure, mmHg

Systolic

127 ± 9

128 ± 13

.882

Diastolic

77 ± 7

76 ± 9

.664

BUN (Urea nitrogen), mg/dL

22.24 ± 8.73

20.13 ± 8.47

.878

Creatinine, mg/dL

1.00 ± 0.49

1.09 ± 0.61

.545

eGFR

80.5 ± 26.0

79.1 ± 24.5

.837

Cholesterol, mg/dL

153 ± 43

170 ± 41

.156

Triglyceride, mg/dL

128 ± 60

129 ± 76

.976

HDL, mg/dL

46 ± 9

52 ± 14

.124

LDL, mg/dL

87 ± 40

89 ± 33

.858

  1. *P-values for the difference between the good and poor responder groups were obtained. DM: diabetes mellitus; CST: central subfield thickness; BCVA: best-corrected visual acuity; BUN, blood urea nitrogen; eGFR: estimated glomerular filtration rate; HDL: high-density lipoprotein; LDL: low-density lipoprotein.
Back to article page